Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis
Status:
Completed
Trial end date:
2006-07-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate that Olopatadine 0.2% is superior to vehicle in
the treatment of the signs and symptoms associated with allergic conjunctivitis or
rhinoconjunctivitis.